EVMN on NYSE
Evommune, Inc.
American pharmaceutical preparations company based in Palo Alto.
Price unavailable
Last updated Oct 18, 2026.
Overview
Compare with Tonix Pharmaceuticals, PALATIN TECHNOLOGIES INC or Spero Therapeutics, Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-623.6%Operating margin3
-529.8%Net margin3
85.7%Revenue growth, 20253
-33.5%Return on equity3
-$76.7MFree cash flow3
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development100¢$74.0M
Out of $13.0M in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| License revenue | $13.0M | $7.0M |
| Total revenue | $13.0M | $7.0M |
| Research and development | $74.0M | $64.2M |
| General and administrative | $20.0M | $12.8M |
| Total operating expenses | $94.1M | $77.0M |
| Loss from operations | -$81.1M | -$70.0M |
| Change in fair value of convertible preferred stock forward | $8.9M | |
| Interest income | $3.3M | $3.2M |
| Other expense, net | -$50.0K | -$37.0K |
| Total other income, net | $12.2M | $3.2M |
| Net loss | -$68.9M | -$66.8M |
| Deemed dividend | $1.5M | |
| Net loss attributable to common stockholders | -$68.9M | -$68.3M |
| Basic net loss per share of common stock | -$11.22 | -$45.29 |
| Diluted net loss per share of common stock | -$11.22 | -$45.29 |
| Weighted average basic shares of common stock outstanding | 6.1M shares | 1.5M shares |
| Weighted average diluted shares of common stock outstanding | 6.1M shares | 1.5M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $44.1M | $16.3M | |
| Short-term investments | $105.1M | $55.8M | |
| Prepaid expenses and other current assets | $4.3M | $1.9M | |
| Total current assets | $153.5M | $74.0M | |
| Operating lease right-of-use assets, net | $1.5M | $472.0K | |
| Property and equipment, net | $994.0K | $1.3M | |
| Long-term investments | $67.5M | ||
| Restricted cash | $1.4M | $208.0K | |
| Other non-current assets | $101.0K | $61.0K | |
| Total assets | $224.9M | $76.1M | |
| Accounts payable | $7.8M | $8.3M | |
| Accrued liabilities | $9.5M | $6.7M | |
| Operating lease liability, current portion | $242.0K | $487.0K | |
| Convertible preferred stock forward | $8.9M | ||
| Deferred revenue | $3.0M | ||
| Other current liabilities | $364.0K | $573.0K | |
| Total current liabilities | $17.9M | $28.0M | |
| Operating lease liability, non-current portion | $1.3M | ||
| Financing lease liability | $181.0K | $535.0K | |
| Total liabilities | $19.4M | $28.5M | |
| Convertible preferred stock: $0.0001 par value -10,000,000 and 157,657,729 shares authorized at December 31, 2025 and December 31, 2024, and 0 and 116,716,142 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively, (liquidation preference $0 and $210,328 at December 31, 2025 and December 31, 2024, respectively) | $0 | $191.8M | |
| Common stock, par value $0.0001 - 500,000,000 and 223,593,879 shares authorized at December 31, 2025 and December 31, 2024, respectively; 31,524,093 and 1,551,420 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $3.0K | $0 | |
| Additional paid-in capital | $426.7M | $8.0M | |
| Accumulated deficit | -$221.1M | -$152.2M | |
| Total stockholders' equity (deficit) | $205.6M | -$144.2M | -$77.7M |
| Total liabilities, convertible preferred stock, and stockholders' equity (deficit) | $224.9M | $76.1M | |
| Convertible preferred stock, par value | $0.00 | $0.00 | |
| Convertible preferred stock, shares authorized | 10.0M shares | 157.7M shares | |
| Convertible preferred stock, shares issued | 0 shares | 116.7M shares | |
| Convertible preferred stock, shares outstanding | 0 shares | 116.7M shares | |
| Convertible preferred stock, liquidation preference | $0 | $210.3M | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 500.0M shares | 223.6M shares | |
| Common stock, shares issued | 31.5M shares | 1.6M shares | |
| Common stock, shares outstanding | 31.5M shares | 1.6M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $44.1M | $16.3M | |
| Short-term investments | $105.1M | $55.8M | |
| Prepaid expenses and other current assets | $4.3M | $1.9M | |
| Total current assets | $153.5M | $74.0M | |
| Operating lease right-of-use assets, net | $1.5M | $472.0K | |
| Property and equipment, net | $994.0K | $1.3M | |
| Long-term investments | $67.5M | ||
| Restricted cash | $1.4M | $208.0K | |
| Other non-current assets | $101.0K | $61.0K | |
| Total assets | $224.9M | $76.1M | |
| Accounts payable | $7.8M | $8.3M | |
| Accrued liabilities | $9.5M | $6.7M | |
| Operating lease liability, current portion | $242.0K | $487.0K | |
| Convertible preferred stock forward | $8.9M | ||
| Deferred revenue | $3.0M | ||
| Other current liabilities | $364.0K | $573.0K | |
| Total current liabilities | $17.9M | $28.0M | |
| Operating lease liability, non-current portion | $1.3M | ||
| Financing lease liability | $181.0K | $535.0K | |
| Total liabilities | $19.4M | $28.5M | |
| Convertible preferred stock: $0.0001 par value -10,000,000 and 157,657,729 shares authorized at December 31, 2025 and December 31, 2024, and 0 and 116,716,142 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively, (liquidation preference $0 and $210,328 at December 31, 2025 and December 31, 2024, respectively) | $0 | $191.8M | |
| Common stock, par value $0.0001 - 500,000,000 and 223,593,879 shares authorized at December 31, 2025 and December 31, 2024, respectively; 31,524,093 and 1,551,420 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $3.0K | $0 | |
| Additional paid-in capital | $426.7M | $8.0M | |
| Accumulated deficit | -$221.1M | -$152.2M | |
| Total stockholders' equity (deficit) | $205.6M | -$144.2M | -$77.7M |
| Total liabilities, convertible preferred stock, and stockholders' equity (deficit) | $224.9M | $76.1M | |
| Convertible preferred stock, par value | $0.00 | $0.00 | |
| Convertible preferred stock, shares authorized | 10.0M shares | 157.7M shares | |
| Convertible preferred stock, shares issued | 0 shares | 116.7M shares | |
| Convertible preferred stock, shares outstanding | 0 shares | 116.7M shares | |
| Convertible preferred stock, liquidation preference | $0 | $210.3M | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 500.0M shares | 223.6M shares | |
| Common stock, shares issued | 31.5M shares | 1.6M shares | |
| Common stock, shares outstanding | 31.5M shares | 1.6M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$68.9M | -$66.8M |
| Stock-based compensation expense | $5.9M | $1.7M |
| Accretion of discount on investments | -$1.8M | -$1.8M |
| Depreciation and amortization | $1.4M | $1.3M |
| Change in fair value of convertible preferred stock forward | -$8.9M | |
| Prepaid expenses and other assets | -$2.4M | -$1.0M |
| Accounts payable | -$837.0K | $6.5M |
| Accrued liabilities | $2.8M | $2.7M |
| Operating lease liabilities | -$730.0K | -$769.0K |
| Deferred revenue | -$3.0M | |
| Net cash used in operating activities | -$76.4M | -$58.2M |
| Purchases of investments | -$199.2M | -$90.3M |
| Maturities of investments | $84.1M | $86.3M |
| Purchase of property and equipment | -$235.0K | -$88.0K |
| Net cash used in investing activities | -$115.3M | -$4.0M |
| Proceeds from the sale of common stock in initial public offering, net of offering costs paid | $157.3M | |
| Proceeds from issuance of convertible preferred stock, net of issuance costs | $65.2M | $49.8M |
| Proceeds from exercise of stock options | $6.0K | $13.0K |
| Principal payments of finance lease liability | -$373.0K | -$208.0K |
| Principal payments of financing obligation | -$158.0K | -$215.0K |
| Taxes paid related to net share settlement of equity awards | -$1.2M | |
| Net cash provided by financing activities | $220.8M | $49.4M |
| Net increase (decrease) in cash, cash equivalents and restricted cash | $29.0M | -$12.8M |
| Cash paid for interest | $7.0K | $34.0K |
| Issuance of common stock upon conversion of convertible preferred stock | $257.0M | |
| Unpaid fixed asset purchases | $35.0K | |
| Vesting of early exercised stock options | $40.0K | $50.0K |
| Assets acquired under finance leases | $10.0K | $1.0M |
| Deferred offering costs in accounts payable | $294.0K | |
| Operating lease liabilities arising from obtaining right-of-use assets | $1.8M | |
| Deemed dividend from trigger of anti-dilution provision feature | $1.5M |
No quarter-by-quarter statement was filed.
Leadership
Who has led Evommune, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
- Chief executive officerLuis C. Pena Nov 5, 2025 to now6
- PresidentLuis C. Pena Nov 5, 2025 to now6
- Chief financial officerKyle Carver Nov 5, 2025 to now7
Board members and other officers (12)
- EVP, OperationsJanice Suzann Drew Nov 5, 2025 to now8
- Chief Scientific OfficerJeegar Pravinkumar Patel Nov 5, 2025 to now9
- Board member7. Cooperative Ua Lsp Feb 19, 2026 to now10
- Board memberArthur S. Kirsch Nov 5, 2025 to now11
- Board memberBenjamin F. McGraw Iii. Nov 5, 2025 to now12
- Board memberDavid E. Cohen Nov 5, 2025 to now13
- Board memberDerek Dirocco Nov 5, 2025 to now14
- Board memberLuis C. Pena Nov 5, 2025 to now6
- Board memberPeter Kolchinsky Nov 5, 2025 to now15
- Board memberRajeev M. Shah Nov 5, 2025 to now15
- Board memberRobert Lorne Hopfner Nov 5, 2025 to now16
- Board memberWeegen Felice Isabel Verduyn-Van Nov 5, 2025 to now17
Timeline
- Nov 5, 2025New chief executive Luis C. Pena becomes CEO6
Filings
135 filings to the SEC since October 2021: 1 annual reports, 3 quarterly reports, 15 major events, 65 insider forms, 9 large holders, 4 private raises, 38 other. The latest 20:
- Oct 15, 20264 PRIMARY DOCUMENT EDGAR
- Oct 1, 20268-K EDGAR
- Sep 23, 20268-K EDGAR
- Sep 15, 20268-K EDGAR
- Sep 9, 2026424B3 EDGAR
- Sep 9, 20268-K EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 14, 2026SCHEDULE 13G EDGAR
- Aug 6, 2026424B3 EDGAR
- Aug 6, 202610-Q EDGAR
- Aug 6, 20268-K EDGAR
- Jul 30, 20268-K EDGAR
- Jul 16, 2026SCHEDULE 13G EDGAR
- Jul 10, 20264 PRIMARY DOCUMENT EDGAR
- Jul 8, 20264 PRIMARY DOCUMENT EDGAR
- Jun 29, 2026424B3 EDGAR
- Jun 29, 20268-K EDGAR
- Jun 24, 20264 PRIMARY DOCUMENT EDGAR
- Jun 24, 20264 PRIMARY DOCUMENT EDGAR
- Jun 24, 20264 PRIMARY DOCUMENT EDGAR
The 135 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 9 such filings since October 2021:
- Aug 14, 2026SCHEDULE 13G/A
- Aug 14, 2026SCHEDULE 13G
- Jul 16, 2026SCHEDULE 13G
- Feb 19, 2026SCHEDULE 13D/A
- Feb 17, 2026SCHEDULE 13D/A
- Feb 13, 2026SCHEDULE 13G
- Nov 17, 2025SCHEDULE 13G
- Nov 17, 2025SCHEDULE 13D
- Nov 14, 2025SCHEDULE 13D
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Money raised
Private offerings the company reported to the SEC on Form D.
- Oct 30, 2024Raised $115.5 million in a private offering of equity Form D: 25 investors so far Form D
- Mar 28, 2023Raised $57.5 million in a private offering of equity Form D: 16 investors so far Form D
- Aug 31, 2021Raised $81.8 million in a private offering of equity Form D: $84.4 million offered in all Form D
- Jun 22, 2020Raised $12.5 million in a private offering of equity Form D: 18 investors so far Form D
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| EQT Fund Management S.a r.l. | 5,288,313 | $70.3M | 8.1% | +358,680 |
| Ra Capital Management, L.P. | 3,494,638 | $46.4M | 0.4% | No change |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,926,943 | $25.6M | 8.3% | No change |
| Jpmorgan Chase & Co | 1,553,132 | $23.4M | 0.0% | +93,712 |
| Rtw Investments, LP | 1,502,235 | $20.0M | 0.2% | No change |
| Nan Fung Group Holdings Ltd | 1,441,032 | $19.2M | 14.6% | No change |
| Point72 Asset Management, L.P. | 1,435,049 | $19.1M | 0.0% | +1,398,472 |
| Andera Partners | 1,391,990 | $18.5M | 9.0% | −505,372 |
| Eventide Asset Management, LLC | 1,209,129 | $16.1M | 0.2% | No change |
| Vestal Point Capital, LP | 1,000,000 | $13.3M | 0.3% | New |
| Jupiter Topco LLC | 896,700 | $11.9M | 0.0% | New |
| BlackRock, Inc. | 886,538 | $11.8M | 0.0% | +212,967 |
| Vanguard Capital Management LLC | 881,895 | $11.7M | 0.0% | +426,844 |
| Baker Bros. Advisors LP | 847,390 | $11.3M | 0.1% | No change |
| Defilade Capital Management, L.P. | 793,145 | $10.5M | 1.4% | +114,556 |
| American Century Companies Inc | 755,018 | $10.0M | 0.0% | +262,080 |
| Alyeska Investment Group, L.P. | 704,425 | $9.4M | 0.0% | −21,937 |
| Balyasny Asset Management L.P. | 457,015 | $6.1M | 0.0% | New |
| Velan Capital Investment Management LP | 451,255 | $6.0M | 3.7% | +5,000 |
| UBS Group AG | 413,553 | $5.5M | 0.0% | +115,178 |
| Federated Hermes, Inc. | 325,000 | $4.3M | 0.0% | No change |
| Great Point Partners LLC | 325,000 | $4.3M | 1.0% | No change |
| Freestone Grove Partners LP | 306,328 | $4.1M | 0.0% | −30,963 |
| Geode Capital Management, LLC | 301,759 | $4.0M | 0.0% | +53,148 |
| State Street Corp | 293,516 | $3.9M | 0.0% | +114,005 |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGAREvommune, Inc. filings on SEC EDGAR
- 2SEC EDGAREvommune, Inc. filings on SEC EDGAR
- 3SEC EDGAREvommune, Inc. 10-K for fiscal 2025
- 4SEC EDGAREvommune, Inc. 10-Q for fiscal 2026
- 5SEC EDGAREvommune, Inc. 10-Q for fiscal 2026
- 6
- 7SEC EDGARKyle Carver, Chief financial officer
- 8SEC EDGARJanice Suzann Drew, EVP, Operations
- 9
- 10SEC EDGAR7. Cooperative Ua Lsp, Board member
- 11SEC EDGARArthur S. Kirsch, Board member
- 12
- 13SEC EDGARDavid E. Cohen, Board member
- 14SEC EDGARDerek Dirocco, Board member
- 15SEC EDGARPeter Kolchinsky, Board member
- 16SEC EDGARRobert Lorne Hopfner, Board member
- 17